KIF20A-10-66(KIF20A-10-66) - 药物靶点：CDH3_在研适应症：胰腺癌_专利_临床

概要

基本信息

药物类型

合成肽疫苗、治疗性疫苗

别名

靶点

CDH3

作用方式

抑制剂

作用机制

CDH3抑制剂(钙粘附蛋白3抑制剂)

治疗领域

肿瘤消化系统疾病内分泌与代谢疾病

在研适应症

胰腺癌

非在研适应症-

原研机构

OncoTherapy Science, Inc.

在研机构

OncoTherapy Science, Inc.

非在研机构-

权益机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 KIF20A-10-66 相关的临床结果

登录后查看更多信息

100 项与 KIF20A-10-66 相关的转化医学

登录后查看更多信息

100 项与 KIF20A-10-66 相关的专利（医药）

登录后查看更多信息

1

项与 KIF20A-10-66 相关的文献（医药）

2012-01-01·Journal of Biomedicine and Biotechnology

Identification of HLA-A24-Restricted Novel T Cell Epitope Peptides Derived from P-Cadherin and Kinesin Family Member 20A

Article

作者: Watanabe, Tomohisa ; Nakagawa, Hidewaki ; Miyazawa, Motoki ; Osawa, Ryuji ; Nakamura, Yusuke ; Takeda, Kazuyoshi ; Tani, Masaji ; Yoshimura, Sachiko ; Tsunoda, Takuya ; Yamaue, Hiroki

We here identified human leukocyte antigen-(HLA-)A∗2402-restricted epitope peptides from Cadherin 3, type 1, P-cadherin (CDH3) and kinesin family member 20A (KIF20A) that were found to be specifically expressed in cancer cells through genome-wide expression profile analysis. CDH3-10-807 peptide and KIF20A-10-66 peptide successfully induced specific CTL clones, and these selectively responded to COS7 cells expressing both HLA-A∗2402 and respective protein while did not respond to parental cells or COS7 cells expressing either HLA-A∗2402 or respective protein. Furthermore, CTL clones responded to cancer cells that endogenously express HLA-A∗2402 and respective protein, suggesting that CDH3-10-807 peptide and KIF20A-10-66 peptide are naturally presented on HLA-A∗2402 molecule of human cancer cells. Our results demonstrated that CDH3-10-807 peptide and KIF20A-10-66 peptide are novel HLA-A24-restricted tumor-associated antigens and would be applicable for CTL-inducing cancer therapies.

100 项与 KIF20A-10-66 相关的药物交易

登录后查看更多信息